Skip to main content
Questions about giving or our research? Call us — (800) 321-2873 Donor help Search

by
New Cancer Type
October 28, 2021

[vc_row][vc_column][vc_column_text] Revolutionary Drug Platform Improves Effectiveness and Tolerability of Cancer Treatment for Multiple Myeloma [caption id="attachment_45717" align="alignright" width="156"] Jerimiah A. Johnson, Ph.D. Massachusetts Institute of Technology, Boston, MA[/caption] The toxicity and side effects of many treatments for cancer often limit their potential effectiveness for many patients. Chemist Dr....

by
New Cancer Type
October 28, 2021

[vc_row][vc_column][vc_column_text] Developing New Treatment for Childhood Brain Cancer, Meduloblastoma [caption id="attachment_45706" align="alignright" width="156"] Cesare Spadoni, Ph.D., MBA University of London[/caption] In 2017, NFCR began support for the research of Dr. Cesare Spadoni, who lost his daughter to cancer and Mr. Ricardo Garcia, whose son is a cancer survivor....

by
New Cancer Type
October 28, 2021

[vc_row][vc_column][vc_column_text] New Treatment for Patients with Advanced Breast Cancer in Phase I Clinical Trial [caption id="attachment_45657" align="alignright" width="153"] Ronald A. DePinho, M.D. Univ. of Texas MD Anderson Cancer Center, Houston, Texas[/caption] STAT3 is a major signaling protein in cells. Hyperactivation of STAT3 occurs in over 50% of cancers...

by
New Cancer Type
October 28, 2021

[vc_row][vc_column][vc_column_text] New Treatment for Rhabdomyosarcoma in Children: Clinical Trial Beginning Soon [caption id="attachment_45706" align="alignright" width="156"] Cesare Spadoni, Ph.D., MBA University of London[/caption] Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma and is aggressive and highly malignant.  It develops from skeletal muscle cells that have failed to fully...

by
New Cancer Type
October 28, 2021

[vc_row][vc_column][vc_column_text] New Treatment for Colorectal Cancer Patients in Phase I Clinical Trial [caption id="attachment_45657" align="alignright" width="153"] Ronald A. DePinho, M.D. Univ. of Texas MD Anderson Cancer Center, Houston, Texas[/caption] STAT3 is a major signaling protein in cells. Hyperactivation of STAT3 occurs in over 50% of cancers, including colorectal...

by
New Cancer Type
October 28, 2021

[vc_row][vc_column][vc_column_text] New Treatment for Patients with Advanced Head and Neck Cancer in Phase I Clinical Trial [caption id="attachment_45657" align="alignright" width="153"] Ronald A. DePinho, M.D. Univ. of Texas MD Anderson Cancer Center, Houston, Texas[/caption] STAT3 is a major signaling protein in cells. It is hyperactivated in over 50% of...

by
New Cancer Type
October 28, 2021

[vc_row][vc_column][vc_column_text] Phase II Clinical Trial of Botanical Drug with Multiple Anti-Cancer Properties Treating Patients with Hepatitis B- Associated Liver Cancer [caption id="attachment_45683" align="alignright" width="154"] Yung-Chi Cheng, Ph.D. Yale University, New Haven, CT[/caption] Dr. Yung-Chi Cheng and his team developed a four-herb formulation into YIV-906.  The botanical drug has...

by
New Cancer Type
October 28, 2021

[vc_row][vc_column][vc_column_text] New Treatment for Patients with Advanced Lung Cancer in Phase I Clinical Trial [caption id="attachment_45657" align="alignright" width="153"] Ronald A. DePinho, M.D. Univ. of Texas MD Anderson Cancer Center, Houston, Texas[/caption] STAT3 is a major signaling protein in cells. It is hyperactivated in over 50% of cancers including...

by
New Cancer Type
October 28, 2021

[vc_row][vc_column][vc_column_text] New Treatment for Advanced Cancers in Phase I Clinical Trial [caption id="attachment_45657" align="alignright" width="153"] Ronald A. DePinho, M.D. Univ. of Texas MD Anderson Cancer Center, Houston, Texas[/caption] STAT3 is a major signaling protein in cells. It is hyperactivated in over 50% of cancers. This results in abnormal...

by
New Cancer Type
October 28, 2021

[vc_row][vc_column][vc_column_text] Specialized Antibodies to Target Cells Around Pancreatic Cancer: Making Immunotherapy an Effective Treatment [caption id="attachment_45682" align="alignright" width="169"] Daniel D. Von Hoff, M.D., FACP Translational Genomics Research Institute, Phoenix, AZ[/caption] Dr. Daniel Von Hoff, a pioneer and world-leading physician-scientist in translational medicine, has personally been involved in over 200...